|
gptkbp:instanceOf
|
opioid
|
|
gptkbp:approvedBy
|
1978
|
|
gptkbp:ATCCode
|
N02AF01
|
|
gptkbp:bioavailability
|
60–70% (nasal)
|
|
gptkbp:brand
|
gptkb:Stadol
|
|
gptkbp:CASNumber
|
42408-82-2
|
|
gptkbp:contraindication
|
respiratory depression
acute asthma
hypersensitivity to butorphanol
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugClass
|
gptkb:opioid_analgesics
|
|
gptkbp:eliminationHalfLife
|
5-6 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C21H29NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Butorphanol
|
|
gptkbp:IUPACName
|
(−)-17-(Cyclobutylmethyl)morphinan-3,14-diol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:meltingPoint
|
218–219 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
80%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201202
4515032
5361110
|
|
gptkbp:receptorActivity
|
kappa-opioid receptor agonist
partial mu-opioid receptor agonist/antagonist
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
nasal spray
|
|
gptkbp:sideEffect
|
nausea
dizziness
sweating
respiratory depression
sedation
dysphoria
|
|
gptkbp:UNII
|
YO3Y2D6CBZ
|
|
gptkbp:usedFor
|
pain management
migraine treatment
labor pain
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV_controlled_substances
|
|
gptkbp:bfsLayer
|
7
|